<SEC-DOCUMENT>0001193125-23-199158.txt : 20230731
<SEC-HEADER>0001193125-23-199158.hdr.sgml : 20230731
<ACCEPTANCE-DATETIME>20230731163001
ACCESSION NUMBER:		0001193125-23-199158
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20230727
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230731
DATE AS OF CHANGE:		20230731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Annexon, Inc.
		CENTRAL INDEX KEY:			0001528115
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				275414423
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39402
		FILM NUMBER:		231127731

	BUSINESS ADDRESS:	
		STREET 1:		1400 SIERRA POINT PARKWAY
		STREET 2:		BLDG C, SUITE 200
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		(650)-822-5500

	MAIL ADDRESS:	
		STREET 1:		1400 SIERRA POINT PARKWAY
		STREET 2:		BLDG C, SUITE 200
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d418528d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:annx="http://annexonbio.com/20230727" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-07-27_to_2023-07-27">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-07-27_to_2023-07-27">0001528115</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="annx-20230727.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-07-27_to_2023-07-27"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-07-27</xbrli:startDate> <xbrli:endDate>2023-07-27</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-07-27_to_2023-07-27">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-07-27_to_2023-07-27" format="ixt:datemonthdayyearen">July&#160;27, 2023</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-07-27_to_2023-07-27">ANNEXON, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-07-27_to_2023-07-27" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-07-27_to_2023-07-27">001-39402</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-07-27_to_2023-07-27">27-5414423</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-07-27_to_2023-07-27">1400 Sierra Point Parkway</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-07-27_to_2023-07-27">Bldg C</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="duration_2023-07-27_to_2023-07-27">Suite 200</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-07-27_to_2023-07-27">Brisbane</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-07-27_to_2023-07-27" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-07-27_to_2023-07-27">94005</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices) (Zip Code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-07-27_to_2023-07-27">(650)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-07-27_to_2023-07-27">822-5500</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-07-27_to_2023-07-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-07-27_to_2023-07-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-07-27_to_2023-07-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-07-27_to_2023-07-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-07-27_to_2023-07-27">Common Stock, par value $0.001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-07-27_to_2023-07-27">ANNX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-07-27_to_2023-07-27" format="ixt-sec:exchnameen">The Nasdaq Stock Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company &#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-07-27_to_2023-07-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies of the press releases, dated July&#160;27, 2023, announcing the appointment of Jamie Dananberg, M.D. as Chief Medical Officer of Annexon, Inc. (the &#8220;Company&#8221;), and dated July&#160;30, 2023, announcing results from the ongoing ARCHER trial in patients with geographic atrophy (GA), as presented at the ASRS 2023 Annual Meeting, are furnished as Exhibits 99.1 and 99.2, respectively, hereto and are incorporated by reference herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item&#160;7.01 of this Current Report on Form <span style="white-space:nowrap">8-K</span> and Exhibits 99.1 and 99.2 attached hereto shall not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section&#160;11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&#160;27, 2023, Dr.&#160;Dananberg commenced employment as Chief Medical Officer of the Company. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap">Exhibit<br />No.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d418528dex991.htm">Press Release, dated July&#160;27, 2023, titled &#8220;Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer.&#8221; </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d418528dex992.htm">Press Release, dated July&#160;30, 2023, titled &#8220;Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy.&#8221; </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File, formatted in inline XBRL.</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom" colspan="3">Dated: July&#160;31, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Annexon, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jennifer Lew</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Jennifer Lew</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President and Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d418528dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g418528g0731095114691.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief
Medical Officer </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BRISBANE, Calif., July</B><B></B><B>&nbsp;27, 2023 </B>- Annexon, Inc. (&#147;Annexon&#148;) (Nasdaq: ANNX), a clinical-stage
biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the appointment of Jamie Dananberg, M.D., as chief
medical officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are delighted to join forces with Jamie during this exciting time for Annexon. He will add significant translational and
development expertise to our platform approach that has demonstrated robust functional benefit across several disorders and is well positioned to shift the treatment paradigm for complement-mediated diseases,&#148; said Douglas Love, president and
chief executive officer of Annexon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am impressed with the data demonstrated to date by Annexon&#146;s upstream complement approach which has the
potential to benefit millions of patients impacted with classical complement-mediated disorders,&#148; said Dr.&nbsp;Dananberg. &#147;With data supporting proof of concept across multiple diseases, several advanced-stage programs at key inflection
points, additional data readouts on the horizon, and an outstanding collection of experienced drug developers, it&#146;s an exciting time to join the organization and build upon the tremendous work accomplished to date.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Dananberg joins Annexon with more than 20 years of drug development experience across a variety of therapeutic areas in the pharmaceutical and
biotechnology industries. Most recently, he served as the chief medical officer for UNITY Biotechnology, where as one of its earliest employees, he built the medical and broader development organization. Prior to UNITY, Dr.&nbsp;Dananberg served as
executive vice president at Takeda Pharmaceuticals in several roles including head, cardiovascular and metabolism therapeutic area, and as the head of both the therapeutic areas group and experimental/translational medicine. Before joining Takeda,
he spent 16 years at Eli Lilly&nbsp;&amp; Co. where he brought more than 100 programs from discovery to development, leading and supporting efforts through all phases, including the launches of multiple commercial products. Before joining Lilly, he
practiced medicine in endocrinology and metabolism and ran a basic science laboratory at the University of Michigan. Dr.&nbsp;Dananberg received his B.S. and M.D. degrees from Tufts University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Annexon </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annexon (Nasdaq: ANNX) is a clinical-stage
biopharmaceutical company seeking to bring game-changing medicines to patients with classical complement-mediated diseases of the body, brain and eye. The classical complement pathway within the immune system, when overactivated, drives inflammation
in a host of autoimmune, neurodegenerative and ophthalmic diseases. Annexon is advancing a new class of complement medicines targeting the early classical cascade and all downstream pathway components that contribute to disease, while selectively
preserving the beneficial immune functions of other complement pathways. Annexon is rigorously developing a pipeline of diversified product candidates across multiple <FONT STYLE="white-space:nowrap">mid-</FONT> to late-stage clinical trials, with
clinical data anticipated throughout 2023 and beyond. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g418528g0731095114691.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chelcie Lister </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THRUST Strategic Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>chelcie@thrustsc.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sheryl Seapy </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Real Chemistry </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">949-903-4750</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>sseapy@realchemistry.com</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d418528dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g418528g0731095025490.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated
Treatment for Geographic Atrophy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Additional analyses support consistent protection from vision loss </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Annexon to engage with regulatory agencies to determine optimal path forward for ANX007 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company to hold investor conference call on Monday, July&nbsp;31, 2023, at 1:30 p.m. PT / 4:30 p.m. ET </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Brisbane, CA, July</B><B></B><B>&nbsp;30, 2023 &#150; </B>Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class
of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today presented results from the ongoing ARCHER trial in patients with geographic atrophy (GA), underscoring
ANX007&#146;s potentially distinct neuroprotective mechanism of action and demonstration of consistent protection from vision loss. Data were presented during an oral presentation titled, &#147;Treatment of Geographic Atrophy Secondary to <FONT
STYLE="white-space:nowrap">Age-Related</FONT> Macular Degeneration with Intravitreal ANX007: Results of the ARCHER Study,&#148; at the American Society of Retina Specialists (ASRS) 2023 Annual Meeting taking place July&nbsp;28 &#150; August&nbsp;1,
2023 in Seattle. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Notwithstanding recent advances in the field of geographic atrophy, preservation of vision remains a central need for the millions
of people living with GA around the world,&#148; said Jeffrey S.&nbsp;Heier, M.D., director of the Retina Service and Retina Research, Ophthalmic Consultants of Boston,&nbsp;and an investigator in ARCHER. &#147;The results from ARCHER demonstrated
dose and time dependent protection of visual function in GA across multiple measures. I am excited by the potential of ANX007 and its distinct neuroprotective mechanism of action, which could offer physicians a chance to preserve vision in a broad
population of patients.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Topline data reported in May 2023 showed that ANX007 demonstrated statistically significant, dose-dependent protection from
vision loss in patients with GA, measured by best corrected visual acuity (BCVA) &#8805;15 letter loss, a widely accepted functional endpoint. Protection from vision loss was also shown in additional prespecified measures of visual function,
including low luminance visual acuity (LLVA) and low luminance visual deficit (LLVD). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annexon conducted additional analyses to further evaluate the
effect of ANX007 treatment on BCVA and GA lesion area. Results presented today at ASRS included: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Risk reduction for BCVA &#8805;15 letter loss was maintained in a more conservative analysis, in which events
occurring at the last single-point visit were excluded. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ANX007&#146;s impact on BCVA &#8805;15 letter loss was consistent across patients&#146; baseline characteristics,
including lesion size, lesion location, multifocality and others, and was not driven by any one patient subgroup. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In addition to protection against &#8805;15 BCVA letter loss, ANX007&#146;s impact on BCVA &#8805;10 letter loss
and BCVA &#8805;20 letter loss demonstrated consistent, dose-dependent protection from vision loss. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Mean change in BCVA at month 12 was supportive of protection of visual function in a dose-dependent manner.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g418528g0731095025490.jpg" ALT="LOGO">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ANX007 was generally well-tolerated through month 12, with no increase in CNV rates between the treated and sham
arms and no events of retinal vasculitis reported. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as part of an investor conference call taking place Monday,
July&nbsp;31 at 1:30 p.m. PT / 4:30 p.m. ET, Annexon will share additional analyses, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">While the primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not
reach statistical significance in the ARCHER trial, additional analyses showed that ANX007&#146;s effect on lesion size showed a trend toward greater effect in the second six months of study for both treatment groups<B>, </B>suggesting that
ANX007&#146;s impact on lesion growth may increase with time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In a <FONT STYLE="white-space:nowrap">fellow-eye</FONT> analysis, comparison of sham, monthly (EM) and
every-other-month (EOM) treatment groups in the subset of patients with bilateral GA, a consistent dose-dependent trend for protection against &#8805;15 BCVA letter loss at the <FONT STYLE="white-space:nowrap">12-month</FONT> time point was shown.
No protection was demonstrated in sham whereas a 74% reduction for EM and 47% reduction for EOM was demonstrated against the corresponding fellow eye groups. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In a preliminary <FONT STYLE="white-space:nowrap">6-month</FONT>
<FONT STYLE="white-space:nowrap">off-treatment</FONT> analysis assessing vision loss after ANX007 treatment was discontinued, the rate of decline in patients with BCVA &#8805;15 letter loss in the treated groups accelerated to parallel the decline
in the sham group. Benefit gained during therapy was maintained, but the groups progressed in parallel once treatment ended, providing independent support of ANX007&#146;s beneficial impact while on treatment. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">six-month</FONT> <FONT STYLE="white-space:nowrap">off-treatment</FONT> <FONT STYLE="white-space:nowrap">follow-up</FONT>
period of the ARCHER trial is ongoing, and Annexon plans to report final results following study conclusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We&#146;re encouraged by the breadth
and depth of the ARCHER data, which demonstrate robust, dose and time dependent preservation of vision loss in the broad patient population as measured by clinical assessments important to the healthcare community and patients,&#148; said Douglas
Love, chief executive officer of Annexon. &#147;Looking ahead, our priority is to advance ANX007 in GA as efficiently as possible, and we will meet with regulators later this year to determine the optimal path forward.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annexon management will host
a conference call, joined by Dr.&nbsp;Heier, on Monday, July&nbsp;31, 2023 at 1:30 p.m. PT / 4:30 p.m. ET. The webcast and accompanying slides will be available under the &#145;Events&nbsp;&amp; Presentations&#146; section on the
Investors&nbsp;&amp; Media page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days. <FONT STYLE="white-space:nowrap">Dial-in</FONT> information for conference participants may be obtained by
registering for the event here. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARCHER Trial Design </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCHER is a randomized, multi-center, double-masked, sham-controlled Phase 2 clinical trial comparing the safety and efficacy of ANX007 in patients with GA
secondary to <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration (AMD). The study enrolled a total of 270 patients, stratified by GA lesion size, location and choroidal neovascularization (CNV) in the fellow eye at the time of
enrollment. Patients had an average age of 80 years and, importantly, were well balanced for baseline visual acuity (BCVA between 58.3 and 58.5). <FONT STYLE="white-space:nowrap">Ninety-six</FONT> percent of patients enrolled were from the United
States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g418528g0731095025490.jpg" ALT="LOGO">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients were randomized to receive an intravitreal dose of 5mg ANX007 monthly (n=89), 5mg ANX007 every other
month (n=92) or sham monthly or every other month (pooled n=89) for a treatment period of 12 months, followed by a <FONT STYLE="white-space:nowrap">six-month</FONT> <FONT STYLE="white-space:nowrap">off-treatment</FONT> period. The primary outcome
measure of the study was the rate of change in GA lesion growth (slope) from baseline as measured by fundus autofluorescence (FAF) through 12 months for the study eye. The study included multiple <FONT STYLE="white-space:nowrap">pre-specified</FONT>
visual function measures to assess the effects of ANX007 on vision: change from baseline in BCVA, change from baseline in <FONT STYLE="white-space:nowrap">low-luminance</FONT> best corrected visual acuity (LLVA) and change in baseline from <FONT
STYLE="white-space:nowrap">low-luminance</FONT> visual acuity deficit (LLVD). Top line results from the study were reported in May 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ANX007
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GA is a disease of vision loss driven by the loss of photoreceptor cells, a type of neuron. Annexon was founded on the discovery that C1q, the
initiating molecule of the classical complement cascade, is a driver of neurodegenerative disease. C1q binds to synapses (neuronal connections) in disease, triggering activation of the classical complement cascade with immune cell recruitment,
neuroinflammation, synapse loss, and neuronal damage. In GA, C1q anchors classical pathway activation on photoreceptor cell synapses and outer segments to cause inflammation and photoreceptor cell loss. Inhibiting C1q blocks all downstream
components of the classical cascade to protect synapses and photoreceptors, providing a unique neuroprotective mechanism. Annexon&#146;s neuroprotective mechanism is distinct from inhibition of C3 or C5, which do not inhibit upstream components of
the classical cascade that contribute to photoreceptor damage. Further, selective inhibition of the classical cascade leaves the lectin and alternative complement pathways in place for normal homeostatic and immune functions. Preclinical models have
demonstrated that inhibition of C1q protected photoreceptor synapses and cells and importantly, photoreceptor cell function. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Geographic Atrophy
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Geographic atrophy (GA), also known as atrophic <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration (AMD) or dry AMD, has a
genetic link to aberrant complement activity and can lead to blindness caused by damaged and dying retinal cells. It is estimated that one million people in the United States and five million people globally suffer from GA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Annexon </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annexon (Nasdaq: ANNX) is a clinical-stage
biopharmaceutical company seeking to bring game-changing medicines to patients with classical complement-mediated diseases of the body, brain and eye. The classical complement pathway within the immune system, when overactivated, drives inflammation
in a host of autoimmune, neurodegenerative and ophthalmic diseases. Annexon is advancing a new class of complement medicines targeting the early classical cascade and all downstream pathway components that contribute to disease, while selectively
preserving the beneficial immune functions of other complement pathways. Annexon is rigorously developing a pipeline of diversified product candidates across multiple <FONT STYLE="white-space:nowrap">mid-</FONT> to late-stage clinical trials, with
clinical data anticipated throughout 2023 and beyond. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E
of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148; &#147;believe,&#148; &#147;contemplate,&#148;
&#147;continue,&#148; &#147;could,&#148; &#147;design,&#148; &#147;due,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;positioned,&#148;
&#147;potential,&#148; &#147;predict,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;suggest,&#148; &#147;target,&#148; &#147;on track,&#148; &#147;will,&#148; &#147;would&#148; and other similar expressions that are predictions of or indicate
future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g418528g0731095025490.jpg" ALT="LOGO">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: topline data from the ARCHER trial of ANX007 in patients with GA;
ANX007&#146;s distinct potential neuroprotective mechanism of action and potential to provide protection from vision loss; the potential for robust, dose and time dependent preservation of vision loss in the broad patient population; continued
development of ANX007; market size; meeting with regulators to determine the optimal path forward; plans to report final results following study conclusion; the potential benefits from treatment with <FONT STYLE="white-space:nowrap">anti-C1q</FONT>
therapy; and continuing advancement of the company&#146;s portfolio. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from
those anticipated, including, but not limited to, risks and uncertainties related to: the ongoing <FONT STYLE="white-space:nowrap">off-treatment</FONT> <FONT STYLE="white-space:nowrap">follow-up</FONT> portion of the ARCHER trial and final results
from the ARCHER trial; the company&#146;s history of net operating losses; the company&#146;s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company&#146;s product candidates; the
effects of public health crises on the company&#146;s clinical programs and business operations; the company&#146;s ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other
properties of the company&#146;s product candidates; the company&#146;s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company&#146;s ability to adequately maintain intellectual
property rights for its product candidates. These and other risks are described in greater detail under the section titled &#147;Risk Factors&#148; contained in the company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT>
and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and the company&#146;s other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities
Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new
information, future events or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The contents of the company&#146;s website at www.annexonbio.com and the webcast and accompanying slides
accessible through the company&#146;s website are not incorporated by reference into this press release. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chelcie Lister </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THRUST Strategic Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>chelcie@thrustsc.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sheryl Seapy </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Real Chemistry </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">949-903-4750</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>sseapy@realchemistry.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>annx-20230727.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 8/1/2023 12:25:52 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:annx="http://annexonbio.com/20230727"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://annexonbio.com/20230727"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="annx-20230727_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="annx-20230727_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>annx-20230727_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 8/1/2023 12:25:52 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>annx-20230727_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 8/1/2023 12:25:52 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="annx-20230727.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g418528g0731095025490.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418528g0731095025490.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V *4# 2(  A$! Q$!_\0
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MYNW;N8KTP<]*YC3C_P (=\1VM3\FG:H 4ST!;[OY-E?H:B\??\E&T3_=A_\
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5Z+-<.Z@CH<$T4478K(W:***0S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g418528g0731095114691.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418528g0731095114691.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V (P# 2(  A$! Q$!_\0
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G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139915827738400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001528115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 27,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANNEXON, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-5414423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1400 Sierra Point Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Bldg C<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">822-5500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANNX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>d418528d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="annx-20230727.xsd" xlink:type="simple"/>
    <context id="duration_2023-07-27_to_2023-07-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
        </entity>
        <period>
            <startDate>2023-07-27</startDate>
            <endDate>2023-07-27</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-07-27_to_2023-07-27">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-07-27_to_2023-07-27"
      id="Hidden_dei_EntityCentralIndexKey">0001528115</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-07-27_to_2023-07-27">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-07-27_to_2023-07-27">2023-07-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-07-27_to_2023-07-27">ANNEXON, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-07-27_to_2023-07-27">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-07-27_to_2023-07-27">001-39402</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-07-27_to_2023-07-27">27-5414423</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-07-27_to_2023-07-27">1400 Sierra Point Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-07-27_to_2023-07-27">Bldg C</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="duration_2023-07-27_to_2023-07-27">Suite 200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-07-27_to_2023-07-27">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-07-27_to_2023-07-27">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-07-27_to_2023-07-27">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-07-27_to_2023-07-27">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-07-27_to_2023-07-27">822-5500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-07-27_to_2023-07-27">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-07-27_to_2023-07-27">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-07-27_to_2023-07-27">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-07-27_to_2023-07-27">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-07-27_to_2023-07-27">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-07-27_to_2023-07-27">ANNX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-07-27_to_2023-07-27">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-07-27_to_2023-07-27">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M<0;+P-X U]=2FK>&_0A0?<,9?0-02P,$%     @ O8/_5I^@&_"Q @  X@P
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ O8/_5@=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" "]@_]6MJ1V=^\    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " "]@_]6F5R<(Q &  "<)P  $P
M    @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +V#_U:O
MERRE> 0  ,\1   8              " @0X(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " "]@_]6GZ ;\+$"  #B#   #0
M    @ &\#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +V#_U:7BKL<P
M !,"   +              "  9@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M +V#_U8<.&7J/P$  #P"   /              "  8$0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " "]@_]6)!Z;HJT   #X 0  &@
M@ 'M$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "]
M@_]699!YDAD!  #/ P  $P              @ '2$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"   <%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d418528d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d418528d8k.htm">d418528d8k.htm</File>
    <File>annx-20230727.xsd</File>
    <File>annx-20230727_lab.xml</File>
    <File>annx-20230727_pre.xml</File>
    <File>d418528dex991.htm</File>
    <File>d418528dex992.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d418528d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d418528d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "annx-20230727_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "annx-20230727_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "annx-20230727.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "annx",
   "nsuri": "http://annexonbio.com/20230727",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d418528d8k.htm",
      "contextRef": "duration_2023-07-27_to_2023-07-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d418528d8k.htm",
      "contextRef": "duration_2023-07-27_to_2023-07-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://annexonbio.com//20230727/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-23-199158-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-199158-xbrl.zip
M4$L#!!0    ( +V#_U;?+6KR/P,  $8+   1    86YN>"TR,#(S,#<R-RYX
M<V2]5M]OVS80?B_0_^&JIPV81$M!VD:(4Z1+ P1(L\%-A[T5M'1VB%*D1E*)
M_=_O2$F.8L>NDQ3-2RC>?7??_:2//RPJ";=HK-!J'*7)* )4A2Z%FH^CQL;<
M%D)$'TY>OSI^$\=P=GYQ!3'<.%?;G+&[N[NDG EEM6P<6;!)H2L&<=SK_WG]
M%?YIK><P08G<(E3<.C3PL1&RS+-1EJ7IZ'WR=@@SR+T]*+G#'-ZSE)'> :19
MGAWFAQF<?H9/P8J":U'A$*KKI1'S&P>_%;]#0)UII5!*7,*Y4%P5@DOXTC/^
M RY4D<"IE##Q,$LT+9I;+)/.ZL*6N2UNL.*O7P%0OI3-%9ELJG'D$]'E83$U
M,M%FSDIGF%O6R$@I)BTTHH@&T!_C-C!4""^Q*^",VVD ]1*?GVR X$HM5MKT
M@0NMID*'^OBDC-YE[P;J)8J5=B!DL4CF^I:18-VTEXO'0\A&HP-&[> HRSB
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M;#NNN^W+U0\Q6Y_B[F8X[>U5NVWH\W]02P,$%     @ O8/_5C>)%S.:!@
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MQ">3+)OJ9A#,Y_-:,F)"2S[+,*2NQ3(-B._;_IW!9_+'ZG1-T@,.5 -)J<Y
MD5]GC"?-J!Y%85@_JWW<E"F@)AY): 9-<A:$ ?9KD#!J1B?-DXBT[\AU'D60
M 4MA4RJG2\7&DXS\'/]"<M65% (XAR6Y88**F%%.^M;Q>](5<8VT.2<](]-H
M4X-Z@J2VCLJ9^*=IGH;&/'G[AN #ZRATWMKR3#76Q5@,%:])-4:[]49@1=ZF
M9K$CFC=R27A^?A[D1XO]-2OKC2<(@[_N;OOQ!%+J(P-D%F^="MTDV5?UIKF3
M8'70]M>LJ?-(MS+.2W] 6F1O#_/)M]U\T^2'D=\(:PN=>)?FE*NJ*LFA!R-B
M7C_WNE_/21'80HHAD_F RN'73Z/3(*/8+--E8!3!E8QG*8C,OK9%<BTREBV[
M8B15FN?AD;RDS8F"4<O#P O?1C-N?NIAH"_'!,J64_Q6:)9..7@DV,AFJG#D
MB"SO?8L-!0$L,A ))#:,2> _R?=R170];&5<R-]^<7-<&N+:6#X%"3!SQLB\
M,<6)\L+@AR\=B7-%>Z@S1>.L6 !NQHE4MI'3(?"65R(*?J2A-J:=F-1O.!T?
M:FA+5#2T":VMXD)(JF(;#M\6B.V.^76/8$H5QO/C"<YN5CU2,BTMSOILLM2H
M5 FHEH?IXW?=(U/%I$+8V.*1F48O<FI<4VZ.P0B4@N1VE?9>E[E%G#<UY#U_
M,)[5:.Q@!HKR+@[WQ>^P/!33'G%U<>TQ;+$UG,%FYY,!EO%06D5-=2$5?5HV
M)\ZQ>03TBM-]<H671,="VA)7G]:688OMHS/85G-##\;,)"JR>YH>3*U<6UUH
MY7XMLU/'F.%R0*JI5'EI^UAAZ,@93O'+CDR.1/B=4%4G^AW[%O"98X!O&(?[
M63H$=1S-35W5T6UZM9S.'>,TH(MN@F5@([9:DKX$VMX@52>XU_@:9Z/N&,YV
MDF"1]?H%U\<0'H>R-$#5,9::M@A#YQ%&KT48N8@P^H;0M;7Y;C*-UR)LN(BP
M\0VA.^OT0C(=?/N@!G(N7@1P4^X(ODW+%MX'-^'E5],/ZE'))V9V[5]"<">&
M(QAW?%N6[FS*%/)YE#JC_&\V/7Z!6![!$8Y;KBU%=_9HS'S25D"/X5;45)=4
MT:=EX\Y>C/D;DC].I#ARJ;ZKJRZC7:^6DSM;*G^BOPQ$1Z;I3*Q7JOI06'O$
MU26VQ[#%YLX.2U]R%K.,B?$=_A@K9JP=QJQ,65U@96[7M#ZXLX'RJ, ,.<"K
MI?RO+',C@7H8C0Z?%I^+4%UZS[FV%-W90]G*IJOU#-3K69;$<89HB7?+U9V-
ME3[$,V,QC(8#EO&#+R5W==7EMNO5<G)G]V2@J+G/L;],A_+@G[LM474);1FU
M>-S9'[%#['H13Z@8PS'_F)=KJPNKW*]EYMH^R'4*:HQC[S<EY]D$Y_<I%4?>
M];4G1'4)/FO;@OP?MD(N@IW2W&*#N6]Y=<0\F;MPL>5?4$L#!!0    ( +V#
M_U;$WC=561   ()I   .    9#0Q.#4R.&0X:RYH=&WM'6MSXK;V>V?Z'S3T
MMI/,!+ -V23D<2=+V"WMAF0@O=VY7SK"%J"NL5S)#G!__3U'LL$\ PF![3:9
MV0U&\M'1T7D?2;GX][#ODT<F%1?!9<XN6#G" E=X/.A>YN*HDS_-D7]???_=
M12^"CM Y4!6/\<M<+XK"2K$X;$N_H)A;Z(K'(C04'<MQ<DG'6.6C4<C4N'>'
MJG9!R&XQ;9GJ'H@@B/OCSH/!H*#!XPM>)(OX1A$ZY:$7D]Q-WQOZ//@R]=J@
MI%^RS\[.BKHU[3K7<SR 8UFE(C:WJ6)I=QH$PW%W>&!#$;2Y*+BBCYB7K!/G
M9(R%XHMP +AV\?/MIY;;8WV:YX&*:.".1X@CN12?LR*TIAVY$F7'/EF!?-)C
M_,)P65\;^@8P5?;Y??/3I'NTN/^D:S&2-% =(?LT G9!2,=YR\D[[S) \L ,
M4X!2YG@*SFF^9(]I"8/S55.=H2*V>C-,F71^5S2-2=?E;((,GM.<SJB'OR,>
M^>SJ-/_K1=%\A._Z+*($(>397S%_O,Q511"Q(,H_ &_FB&N>+G,1&T9%#9$4
M\;UB I00<M$6WNCJPN./1$4CGUWF/*Y"GXZ0_UGNBESP806[,YE\YI[' O,9
MNC0,\Y. ]O%=QBO7?19X\"_ZX--N@L0P:K(.-,=2T_@/Y-:\=9)W3OZ(1.8I
M=]6AOF(7Q2G@<X-Q[S+WL\;C#QCQCUH %!E584A)_7K@L>&O;)3+H+2DPX:H
M62 [Q\ZI;1_/XU><H8QD'29!=3$%SRC'%:4E#L8B6@544'U<YA3OASXRCOZN
M)Q$5%/-\*L^%H?+29BI=*7")UM88KZ"+KBZ*T_-)9C\U8_VL1"S-HQ:@2D)N
MO7IKD#M]C>G%&S]R#[_H<":)1H$M%.]J_=?I!9M]&;%>"#^$%17>^!$D6T8W
M-&)7$]S2-R=M$UR])7W3EO&PXW&*4]094W-"O6)6 HL@J? K(Z_X5I[ZO!M4
M7)@+D[GI]@'WHE[EM'#,@_-,7Y]UHO,^E5T>Y/%SA= X$NDWDG=[R5<(+DR!
MH=+,]YAN!?,<CD%$(JQD'MLBBD1??],6$E!/O['#(5'"YQ[YP=(_N:N??K#?
M6><7Q7#90*6G!W*>/5 &;!F D/D)D XL35[Q_[&*?3I^[M ^]T>5!]YGBC38
M@#1%GP;GNFU@\&X+WSM?L#R_->H/M1O2>KA^J+66HV/M")U6K?I;L_Y0K[7(
M=>.&U#Y7?[YN?*R1ZMWM;;W5JM\U7H2CLPT<?Z>J!TY@)((C<E.H%HAC'9?/
M9O#*#+H.9TXSQ%,2M9 SWSV+,PL6=)MFSG,CI8[]X_SLUY32R612);%HP>Q=
M<=6'N^8MN5 A#<:*J,<CEH=O7 ;&<R!I",9DF1=Q(]P8G8B,)[.^I=9>TK2)
MOB@B*E=O'/,J'+,5&0<MU*PU'DBS=G_7?-B_SKF/I8II$)%(D!9SD><,Q>P2
MN6L2^_C .]P_EJ)#HAY#!&/)(P[OUX9NCP9=1J[=B$"S?58J+\=S9\N+[@^B
MTV2AD!$Y2)\9!?>'J8BP1^A)I&YFWF%E>8B1*H=[[4/5C&NUJ98@)N2[S$&8
M6/$ 0!]>[WET- *,6)"[^B7V1V;!G9,C@F_.*Y4W;;)];>*4M\%NR[G'1(--
MUN4*0_^H 2T;FYCK1J/V^:YQ1.J-:F%!//@"M6!M8_H'M2$%\<=9HY#)\6P)
M542%S,4HR",\(#Q2!!0&R)R<56=O#+V$H5]"&,SET+;/B,M\'[TAG=RT<OHY
MI)Z7/B=C)7-UA>_34+%*^F$UCV08"MTY0PW;LGY,:%>Q$C0K5AKE(6+2_/*F
M@\=2^4>,^R-OIO61R8B[U$^H:R:\L&<"Q]D 3HKSXE=F <)_">XR[1+2+LNW
M):-?,,\)H7^%/@K@D+4)9^NEFQZ79+B)3+%313,2F9D+\ 1@F'6#9Z5WA1-L
M-%4]<(4$HZA54BL"2U45<1#)455X+[)ZF!S%)$;$0BD><5@T>S?,IP.P@$L]
MZ'79(.7YN?ZO0L-G1QJ&R!^XSZ"M#;II\[R@G2^=E2UG*<6^9<(]T&$]R:JY
MFE+/I*)SDC\NV^7R(B]KCHRO(>VG6Q+VY]K]K43=!UH_$"&)@*A DC\A*% >
MU\'+1DZ)_0K(@1_"L[KLT-C6_8C%?I>I*OI]KM37L"JH^8@1VG_P@M2;+5+K
MA[X8,;GW)9E6J*0A"I.5T:H/_D,7\@4A_5:"C"=,P[7G2:94\NL3N/GVQF;!
M+EL6:7$F)27W@D/\<D_EEP$=S5J)HZ<"OGELG(VQ>>][75+=PM"EC8=NQ6":
MB6-93R0A]A!KKC?[*GR\DP]B$&Q.=C!B;1K,N:3K$EX;Q3MY#UXNUW7Z;?O,
M52 (= HX?:ITO03#>P$P_?_R\#D^_14XG]9<4?HE?+$=G9K,#?,/H03"\Y#Z
MA V9&T?\$=,2H.&8.B0',&^"$U^13MV93IODA7[ZX=2Q3\X56#.?A3T1,!)H
M,WF$;HP?8Z!.(%"BL%S@;BY?:>3\:^CWK+4]>'=L'<YSU;.]]D\"[.X]SN:9
MCOJIX^2/CQ?IH445EGTL84-$Y#H,?;"?8"3W+P<?0'V +VYR<5)K$WBD1CJ
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M*T7)%4G:"!&\+;J0M1IC_Q _3C+XVIC\<]/X>SV+W*I_;%P__-:LM9Z3+]0
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M@I^>9T4<^E6R.@K5W\UD4AC(T4B8^-%$IABH3Z.CT0!*@HD0&+NU]HL',J-
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M!> 8N9YW >X1@!2>F0?HJ"4GDVXJC#)E4)><>STI# 8MV=CUQHP7E#*84I#
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M7]V>@X3(?S[Z%R[R_R7._P!02P$"% ,4    " "]@_]6WRUJ\C\#  !&"P
M$0              @ $     86YN>"TR,#(S,#<R-RYX<V102P$"% ,4
M" "]@_]6-XD7,YH&  "X20  %0              @ %N P  86YN>"TR,#(S
M,#<R-U]L86(N>&UL4$L! A0#%     @ O8/_5J?$M*W1!   _BT  !4
M         ( !.PH  &%N;G@M,C R,S W,C=?<')E+GAM;%!+ 0(4 Q0    (
M +V#_U;$WC=561   ()I   .              "  3\/  !D-#$X-3(X9#AK
M+FAT;5!+ 0(4 Q0    ( +V#_U:^E@#-=@@  $L8   1              "
M <0?  !D-#$X-3(X9&5X.3DQ+FAT;5!+ 0(4 Q0    ( +V#_U8;T1%3W1@
M !EG   1              "  6DH  !D-#$X-3(X9&5X.3DR+FAT;5!+!08
1    !@ & '\!  !U00     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
